Runx2

This article provides an in-depth analysis of a 2026 Journal of Translational Medicine study reporting that pseudouridine synthase DKC1 is highly expressed in multiple myeloma and serves as an independent adverse prognostic marker for overall and progression-free survival, refining the ISS staging system for risk stratification. Knockdown, overexpression and inhibitor studies establish that DKC1 promotes proliferation, suppresses apoptosis and drives tumour growth in vivo, while the DKC1 inhibitor pyrazofurin suppresses myeloma activity with minimal organ toxicity.

The mechanistic axis is resolved through transcriptomic screening, RNA immunoprecipitation and carboxymethylated single-base pseudouridylation sequencing, which identify site-specific pseudouridylation of ATF5 mRNA as the link to Bcl-2 upregulation, confirmed by rescue experiments. The role of the Absin D-luciferin sodium salt (abs42017259) in quantitative in vivo bioluminescence imaging of tumour burden is discussed throughout.

High baseline signal in control arms, large within-group variability, poor cross-batch reproducibility and false positives that contradict the literature are common in hormone receptor validation and directed differentiation. The principal cause is often the endogenous steroid hormones, thyroid hormones and fat-soluble vitamins carried by conventional fetal bovine serum. This article analyses the four interference mechanisms involved and describes the four-step preparation process based on a combined activated-charcoal and dextran adsorption principle.

A detailed comparison table sets out how charcoal-treated and conventional serum differ in steroid hormone content, lipophilic small molecules, macromolecular nutrient retention, batch variability, proliferation rate, suitable applications and cost. The recommended product, Absin charcoal-treated fetal bovine serum (abs943), is low in endotoxin, free of mycoplasma and stable between batches.

Charcoal-treated fetal bovine serum is prioritised for four distinct experimental scenarios: nuclear receptor and endocrine pathway research, hormone-dependent tumour models and drug sensitivity screening, directed stem cell differentiation, and endocrine disruptor assessment. This article reviews each of these applications and explains how endogenous hormonal background otherwise produces false positives, uncontrolled differentiation and underestimated drug potency.

Four quality-control metrics are proposed for product selection: the adsorption process and its selectivity, quantified hormone removal efficiency, cell culture performance validation, and microbiological status together with batch-to-batch consistency. Practical considerations are also addressed, including graded cell transition, avoidance of prolonged passaging in the stripped formulation, storage and freeze-thaw management, and aseptic handling.

Endogenous hormones and lipophilic small molecules carried by conventional fetal bovine serum are a recognised confounding variable in hormone receptor validation, directed stem cell differentiation and endocrine pharmacology screening. This article sets out three criteria for determining whether an assay genuinely requires charcoal-treated serum, describes a stepwise adaptation and medium-change protocol that minimises cellular stress, and reviews common misconceptions, including the view that more complete hormone removal is always preferable.

The recommended product, Absin charcoal-treated fetal bovine serum (abs943), is produced by a standardised activated-charcoal/dextran composite adsorption process that removes endogenous lipids, steroid hormones and pigments while preserving the macromolecular nutrients required for cell growth. It is low in endotoxin, free of mycoplasma and consistent between batches, and is suited to hormone pathway validation, directed differentiation, hormone-dependent tumour research and endocrine disruptor screening.

This article describes the explant method for isolating mesenchymal stem cells from umbilical cord tissue, including DPBS washing, vessel removal, 1 mm3 explant seeding, adherence and medium supplementation timing, and the appearance of fibroblast-like outgrowth between days 3 and 14. It defines morphological criteria for distinguishing healthy from unhealthy cultures, namely fibroblast-like appearance, polarised swirling arrangement and even distribution without clustering, as opposed to uneven distribution, clumping, grid-like patterning and poor attachment. The article then provides complete protocols for osteogenic differentiation with Alizarin Red staining of calcium nodules, adipogenic differentiation with Oil Red O staining of lipid droplets, and chondrogenic differentiation in polypropylene tubes with Alcian blue staining of acidic mucopolysaccharides, together with the expected timelines and interpretation criteria for each readout.

Extracellular vesicles of 30-150 nm carry proteins, miRNA, mRNA and lipids and are central to intercellular communication in tumour metastasis, immune regulation, stem cell therapy and liquid biopsy. A major cause of irreproducible exosome data is the substantial load of bovine extracellular vesicles contributed by standard fetal bovine serum, reported at 10^9 to 10^10 particles per mL. This article analyses the four levels at which serum vesicles distort results: particle quantification in NTA, background bands and high-abundance bovine proteins in western blot and proteomics, contamination of sequencing libraries by bovine miRNA and mRNA, and false positives in functional gain- and loss-of-function assays. It also describes the multi-stage ultraspin plus nanofiltration preparation workflow and compares standard and exosome-depleted serum across exosome content, CD63 level, growth factor retention, proliferation rate, attachment and background cleanliness.

This practical guide explains when to use exosome-depleted fetal bovine serum (FBS) and how to standardise cell culture and supernatant collection. It covers four application scenarios in which serum vesicle background must be eliminated: exosome isolation and characterisation by NTA, TEM and marker validation; exosome functional and mechanistic studies; exosome omics and sequencing; and disease microenvironment models with drug delivery development. The guide also details medium exchange timing at 60-70% confluence, a 24-48 hour supernatant collection window, freeze-thaw handling, aseptic practices and cell type compatibility, together with quality-control indicators for selecting a reliable exosome-depleted serum, including quantified removal efficiency, culture performance, origin and safety, and batch stability.

This article provides an overview of proteolysis-targeting chimeras (PROTACs), heterobifunctional small molecules that eliminate pathogenic proteins through the ubiquitin-proteasome system. The architecture comprises three modules: a target-binding ligand, a linker and an E3 ubiquitin ligase ligand, most commonly recruiting CRBN, VHL, MDM2 or IAP. The article reviews the catalytic mechanism of action, the roles of linker chemistry in ternary complex formation, ligand-linker conjugate strategies, and the expanding clinical pipeline targeting AR, ER, BTK, IKZF1/3, BRD9, Bcl-xL and IRAK4, together with emerging modalities such as LYTAC and AUTOTAC.

This article reviews a 2026 Journal of Translational Medicine study on asiaticoside (AC) as an adjuvant for MSLN-targeted CAR-T therapy in ovarian cancer. Single-cell secretome profiling identifies TGF-beta1 as the key immunosuppressive factor that drives CAR-T exhaustion, and AC is shown to restore effector function by inhibiting the TGF-beta/SMAD axis and blocking Treg differentiation. In vitro, 20 uM AC selectively enhances lysis of MSLN-positive SKOV-3 and OVCAR-3 cells but not MSLN-negative ES-2 cells, with no effect on CAR-T viability. In vivo, AC combination therapy suppresses peritoneal and subcutaneous tumour growth without organ toxicity. The mechanistic conclusions were validated by multiplex immunofluorescence using the Absin abs50012-20T four-colour panel for CD3, Ki67, CD31 and DAPI on tumour sections.

This review summarizes a Pharmacological Research study in which small activating RNA was used to upregulate endogenous HIF-1α in non-viral piggyBac-engineered CAR-T cells. HIF1A-overexpressing CAR-T cells showed enhanced cytotoxicity, cytokine secretion and 3D tumor spheroid infiltration under 1% hypoxia through combined GLUT1-driven glycolytic upregulation and Nrf2/PGC-1α-mediated mitochondrial protection, and synergized with an anti-CTLA4 nanobody in vivo without evident organ toxicity. Absin human IL-2, TNF-α and IFN-γ ELISA kits (abs510001 / abs510006 / abs510007) provided the quantitative cytokine readouts across 2D co-cultures, 3D spheroids and mouse serum samples.

This review summarizes an Exploration paper describing an MN-MOF@DHC microneedle patch that combines a Ce-MOF nanozyme with sustained-release dihydrocapsaicin for diabetic wound regeneration. The platform simultaneously addresses oxidative stress overload, persistent chronic inflammation and defective angiogenesis, achieving near-complete wound closure by day 16 in both dorsal full-thickness wound and diabetic foot ulcer models. Absin Triton X-100 (abs9149) served as the universal permeabilization reagent for all immunofluorescence and immunohistochemistry steps, from cultured cells to 20 µm frozen tissue sections, underpinning the M1/M2 phenotyping, vascular and apoptosis imaging data.